miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

BACKGROUND: Drug resistance hampers the efficient treatment of malignancies, including advanced stage ovarian cancer, which has a 5-year survival rate of only 30 %. The molecular processes underlying resistance have been extensively studied, however, not much is known about the involvement of microR...

Full description

Saved in:
Bibliographic Details
Published in:Mol Cancer
Main Authors: van Jaarsveld, Marijn T. M., van Kuijk, Patricia F., Boersma, Antonius W. M., Helleman, Jozien, van IJcken, Wilfred F., Mathijssen, Ron H. J., Pothof, Joris, Berns, Els M. J. J., Verweij, Jaap, Wiemer, Erik A. C.
Format: Artigo
Language:Inglês
Published: BioMed Central 2015
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4650519/
https://ncbi.nlm.nih.gov/pubmed/26576679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0464-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items